Blend Therapeutics is a biopharmaceutical company discovering new classes of medicines that have unique modes of action to result in drugs with differentiated therapeutic properties. The company's proprietary technology, assets and expertise are built around an integrative R&D process that brings together new-molecule drug discovery engine and our patented nanoparticle engineering platform. Using its drug discovery approach, Blend has created a pipeline of new molecules and is initially focused on developing innovative cancer drugs. The company was founded by three leaders in the fields of chemistry and nanomedicine from the Brigham and Women’s Hospital (BWH)–Harvard Medical School (HMS), and Massachusetts Institute of Technology (MIT): Dr. Omid Farokhzad of BWH–HMS, and Dr. Robert Langer and Dr. Stephen J. Lippard of MIT.
Ed Kania is on the Board of Directors.